Статья

Immunogenicity of different forms of middle east respiratory syndrome s glycoprotein

T. Ozharovskaia, O. Zubkova, I. Dolzhikova, A. Gromova, D. Grousova, A. Tukhvatulin, O. Popova, D. Shcheblyakov, D. Scherbinin, A. Dzharullaeva, A. Erokhova, M. Shmarov, S. Loginova, S. Borisevich, B. Naroditsky, D. Logunov, A. Gintsburg,
2021

The Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012 during the first Middle East respiratory syndrome (MERS) outbreaks. MERS-CoV causes an acute lower-respiratory infection in humans, with a fatality rate of ~35.5%. Currently, there are no registered vaccines or means of therapeutic protection against MERS in the world. The MERS-CoV S glycoprotein plays the most important role in the viral life cycle (virus internalization). The S protein is an immunodominant antigen and the main target for neutralizing antibodies. In the present study, the immunogenicities of five different forms of the MERS-CoV S glycoprotein were compared: the full-length S glycoprotein, the full-length S glycoprotein with the transmembrane domain of the G glycoprotein of VSV (S-G), the receptor-binding domain (RBD) of the S glycoprotein, the membrane-fused RBD (the RBD fused with the transmembrane domain of the VSV G glycoprotein (RBD-G)), and the RBD fused with Fc of human IgG1 (RBD-Fc). Recombinant vectors based on human adenoviruses type 5 (rAd5) were used as delivery vehicles. Vaccination with all of the developed rAd5 vectors elicited a balanced Th1/Th2 response in mice. The most robust humoral immune response was induced after the animal had been vaccinated with the membrane-fused RBD (rAd5-RBD-G). Only immunization with membrane forms of the glycoprotein (rAd5-S, rAd5-S-G, and rAd5-RBD-G) elicited neutralizing antibodies among all vaccinated animals. The most significant cellular immune response was induced after vaccination of the animals with the full-length S (rAd5-S). These investigations suggest that the full-length S and the membrane form of the RBD (RBD-G) are the most promising vaccine candidates among all the studied forms of S glycoprotein. © 2019 National Research University Higher School of Economics.

Цитирование

Похожие публикации

Документы

Источник

Версии

  • 1. Version of Record от 2021-04-27

Метаданные

Об авторах
  • T. Ozharovskaia
    Federal Research Centre of Epidemiology, Microbio. named after Honorary Academician N.F. Gamaleya, Ministry of Health of Russian Federation, Gamaleya Str. 18, Moscow, 123098, Russian Federation
  • O. Zubkova
    '48 Central Research Institute', Ministry of Defense of Russian Federation, Oktyabrskaya Str. 11, Sergiev Posad, 141306, Russian Federation
  • I. Dolzhikova
  • A. Gromova
  • D. Grousova
  • A. Tukhvatulin
  • O. Popova
  • D. Shcheblyakov
  • D. Scherbinin
  • A. Dzharullaeva
  • A. Erokhova
  • M. Shmarov
  • S. Loginova
  • S. Borisevich
  • B. Naroditsky
  • D. Logunov
  • A. Gintsburg
Название журнала
  • Acta Naturae
Том
  • 11
Выпуск
  • 1
Страницы
  • 38-47
Издатель
  • Acta Naturae
Тип документа
  • journal article
Тип лицензии Creative Commons
  • CC
Правовой статус документа
  • Свободная лицензия
Источник
  • scopus